Sargramostim in patients with Crohn’s disease: results of a phase 1–2 study
- 168 Downloads
We aimed to assess the tolerability, pharmacokinetics, safety, and efficacy of sargramostim in Japanese patients with active Crohn’s disease (CD).
Patients with moderately to severely active CD were enrolled. Step 1 was an open-label, phase 1 study of 2 μg/kg per day sargramostim administered subcutaneously (SC) for 4 weeks, with an optional 8-week extension with 6 μg/kg per day. Step 2 was an open-label, phase 1–2 study of the tolerability and pharmacokinetics of SC sargramostim 6 μg/kg per day over 4 weeks and of 8-week efficacy and safety. Efficacy variables were the proportion of patients achieving a clinical response [≥100-point decrease from baseline in the CD activity index (CDAI)] and the proportion achieving clinical remission (CDAI ≤ 150 points).
Six patients participated in Step 1; five in Step 2. Serum concentrations of sargramostim peaked within 1 h of administration; mean terminal half-life was 2 h. Maximal serum concentrations increased with the dose. Mean accumulation ratios were 0.998 in Step 1 and 0.673 in Step 2. One of the six patients in the Step-1 extension and none of the five in Step 2 achieved a clinical response. Clinical remission was reported in one patient in each step. A notable decrease in median CDAI scores was observed in the extension and Step 2. In responders, improvement tended to be maintained through the 30-day follow-up. Drug-related adverse events included injection-site reaction, pyrexia, back pain, and bone pain.
The systemic exposure of sargramostim increased dose-dependently. No accumulation in systemic exposure was associated with the repeated once-daily administration. SC sargramostim at 6 μg/kg per day improved median CDAI scores. A minority of patients experienced clinical remission or clinical response.
KeywordsCrohn’s disease activity index (CDAI) Crohn’s disease Inflammatory bowel disease Sargramostim
We thank the members of the NOVEL 9 Study Group. Medical writing assistance and editorial support were provided by Adelphi Inc. and were funded by Bayer Yakuhin Ltd.
- 5.Wilks JN, Viney JL. GM-CSF treatment for Crohn’s disease: a stimulating new therapy? Curr Opin Investig Drugs. 2002;3:1291–6.Google Scholar
- 8.LEUKINE® (sargramostim). Bayer HealthCare Pharmaceuticals, Seattle, WA. Revised April 2008. http://www.leukine.com/hcp/index.jsp. Accessed 28 Sept 2008.
- 9.Neumunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogenic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949–54.Google Scholar
- 10.Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, et al. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol. 1996;14:2976–83.PubMedGoogle Scholar
- 11.Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. Cancer Invest. 1999;17:1–9.PubMedCrossRefGoogle Scholar
- 14.Valentine JF, Fedorak RN, Fredlund P, Feagan BG, for the Sargramostim CD Study Group. Sargramostim induces steroid-free remission in corticosteroid-dependent Crohn’s disease: results of NOVEL 2, a phase II multicenter study. Presented at Digestive Diseases Week, Washington DC, 19–24 May 2007.Google Scholar
- 15.Bayer HealthCare. Phase 3 randomized, double-blind, placebo-controlled induction study of sargramostim (Leukine®) in subjects with active Crohn’s disease. http://www.clinicalstudyresults.org/drugdetails/?inn_name_id=474&sort=c.company_name&page=1&drug_id=2435. Accessed 28 Sept 2008.